drugset / Trial / NCT06437496
68Ga-AAZTA-093 PET/CT: First-in-human Study
RandomizedParallel-groupOpen-labelDiagnostic
Summary
68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with prostate cancer.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2024-07-01
- Completion
- 2024-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-AAZTA-093 | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Subject | 68Ga-AAZTA-093 | Diagnostic / imaging agent | 148 mbq | Intravenous |
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 148 mbq | Intravenous |
| Subject | VIPIVOTIDE TETRAXETAN GALLIUM | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Subject | VIPIVOTIDE TETRAXETAN GALLIUM | Diagnostic / imaging agent | 148 mbq | Intravenous |